

S1 Table. Baseline characteristics according to the first-line treatment

	Total (n=156)		VEGF-TKIs (n=79)		mTORi (n=63)	
	Missing	Summary	Missing	Summary	Missing	Summary
IMDC risk group	1		0		0	
Favorable		36 (23.2)		17 (21.5)		14 (22.2)
Intermediate		91 (58.7)		52 (65.8)		37 (58.7)
poor		28 (18.1)		10 (12.7)		12 (19.1)
MSKCC risk group	1		0		0	
Favorable		37 (23.9)		17 (21.5)		14 (22.2)
Intermediate		96 (61.9)		48 (60.8)		35 (55.6)
Poor		22 (14.2)		14 (17.7)		14 (22.2)
Time from diagnosis to systemic treatment (yr)	1		0		0	
≥ 1		88 (56.8)		45 (57.0)		35 (55.6)
< 1		67 (43.2)		34 (43.0)		28 (44.4)
KPS (%)	9		5		3	
≥ 80		146 (99.3)		74 (100.0)		60 (100.0)
< 80		1 (0.7)		-		-
Hb (IMDC) (g/dL)	83		41		33	
≥ 12		31 (42.5)		19 (50.0)		10 (33.3)
< 12		42 (57.5)		19 (50.0)		20 (66.7)
Hb (MSKCC) (g/dL)	83		41		33	
≥ 13.5 (or 12)		22 (30.1)		15 (39.5)		6 (20.0)
< 13.5 (or 12)		51 (69.9)		23 (60.5)		24 (80.0)
Ca (IMDC) (mg/dL)	89		45		35	
≤ 10.2		61 (91.0)		31 (91.2)		25 (89.3)
> 10.2		6 (9.0)		3 (8.8)		3 (10.7)
Ca (MSKCC) (mg/dL)	89		45		35	
≤ 10		60 (89.6)		31 (91.2)		24 (85.7)
> 10		7 (10.5)		3 (8.8)		4 (14.3)
Neutrophil (×10 ⁹ /L)	83		41		33	
≤ 7		58 (79.5)		28 (73.7)		25 (83.3)
> 7		15 (20.6)		10 (26.3)		5 (16.7)
Platelets (μL)	83		41		33	
≤ 400,000		64 (87.7)		29 (76.3)		30 (100.0)
> 400,000		9 (12.3)		9 (23.7)		-
LDH (U/L)	127		60		55	
≤ 210		7 (24.1)		4 (21.0)		2 (25.0)
> 210		22 (75.9)		15(79.0)		6 (75.0)

Values are presented as number (%). VEGF, vascular endothelial growth factor; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of rapamycin inhibitor; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC, Memorial Sloan Kettering Cancer Center; KPS, Karnofsky performance status; Hb, hemoglobin; LDH, lactate dehydrogenase.